Study finds why asthma drugs help some children but not others

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
The American Journal of Managed Care

FDA Approves Depemokimab for Severe Eosinophilic Asthma

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...
UPI

Clinical trial shows promise for injectable drug to treat asthma

An anti-inflammation injectable drug can reduce mucus buildup and improve breathing among asthma patients, a new clinical trial says. The drug dupilumab (Dupixent) effectively clears up airways ...
Medical Dialogues

FDA Approves Depemokimab-ulaa as First Twice-Yearly Biologic for Severe Eosinophilic Asthma

Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...